Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Non-cash Items (2021 - 2025)

Inhibikase Therapeutics (IKT) has 5 years of Non-cash Items data on record, last reported at $7.7 million in Q4 2025.

  • On a quarterly basis, Non-cash Items fell 3.29% to $7.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $7.7 million, a 3.29% decrease, with the full-year FY2025 number at $7.7 million, down 3.29% from a year prior.
  • Non-cash Items reached $7.7 million in Q4 2025 per IKT's latest filing, down from $8.0 million in the prior quarter.
  • Over the last five years, Non-cash Items for IKT hit a ceiling of $8.0 million in Q4 2024 and a floor of $648979.0 in Q4 2023.
  • A 5-year average of $4.4 million and a median of $3.5 million in 2022 define the central range for Non-cash Items.
  • Peak YoY movement for Non-cash Items: plummeted 81.45% in 2023, then soared 1126.86% in 2024.
  • Tracing IKT's Non-cash Items over 5 years: stood at $2.0 million in 2021, then soared by 74.89% to $3.5 million in 2022, then tumbled by 81.45% to $648979.0 in 2023, then skyrocketed by 1126.86% to $8.0 million in 2024, then dropped by 3.29% to $7.7 million in 2025.
  • Business Quant data shows Non-cash Items for IKT at $7.7 million in Q4 2025, $8.0 million in Q4 2024, and $648979.0 in Q4 2023.